Delivered-To: tjphuhs@gmail.com Received: by 2002:a05:6000:d0:b0:439:fcfb:30e with SMTP id q16csp1404835wrx; Mon, 30 Mar 2026 15:07:49 -0700 (PDT) X-Received: by 2002:a05:6214:20e7:b0:899:fb4e:47aa with SMTP id 6a1803df08f44-89ce8ebf488mr181854596d6.39.1774908469377; Mon, 30 Mar 2026 15:07:49 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1774908469; cv=none; d=google.com; s=arc-20240605; b=Ij0pcGT6/aqAg7P3RAWFrH82+W3w5isLDfbyn2N16V24OWmT+KEs7JhJy8qCKNaCbr rv3NzW5TlFOsnWsf1B8WQnuIeTdm0fI4PwP3NlvFiWGLiW6QrWea2Uxo/zP1IZEg+EtT guD55YV1vRFMRm028bvFXIOXTionYHnNjWmdmXfiFFxHApG27EuH5cFEjWByP+XrvOpS kOIRxhHBg4OhDGR2veLxvS/IrEW3E8arBeS+TGRn3LoDjc+Ur2tgd/7HWMYuY0QiELl7 C6b5s1veBUwi9Q/NuNCtJfHjH/aYQMjBugFaZkgcV9WyiwUurH4QoRZx7XeSfWBjVJKs iPYQ== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=message-id:date:mime-version:sid:subject:reply-to :list-unsubscribe-post:list-unsubscribe:from:feedback-id:to :dkim-signature:dkim-signature; bh=FT5sMOdO/zpAmf/7BcGaaSHFfpJbt4udw6QHWSIGC6A=; fh=Hcu5VqhndQNvtVhwbc8tr7JrSOSQJms/+lG2L+E9gBs=; b=BQLu64vJkEZCMsUlssKJ/lmNDXzY7aKa3HmllA4tVq4CsK8Zmixx5tQezRKJL3fXOO BLdnpvaRAAuM2dKW8fGpPLeSVcBq1ZGGcGld88kHI4dnjYLxsniqRY+V3kI/GbQlmJvZ Ui0w19rzXWvd+snU/hQCFgLJZirH+s1QySwWUPDCg4Ae+3pYUAmltMohUQJhDr6a0Hz6 cFwvaTcI9705CosfwHZNkUHiHE5S4osV90R15g1VhgQUPqvh9wb19h8WjyUZy/iGFhLn CodmtPHcePz5rmllPlbFg4GOjiGZ5OQVLkqHBIGHUcMOY1S6B8il3jh2Ku7jXhdpcUDg 7sZw==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@bhmta.beehiiv.com header.s=bh header.b=dy1gcyWb; dkim=pass header.i=@mail.beehiiv.com header.s=bh header.b=GqQm0gPL; spf=pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.14 as permitted sender) smtp.mailfrom="bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=beehiiv.com Return-Path: Received: from bh186-14.smtp-out.beehiivmail.net (bh186-14.smtp-out.beehiivmail.net. [69.67.186.14]) by mx.google.com with ESMTPS id 6a1803df08f44-89ed14ca148si108017226d6.573.2026.03.30.15.07.49 for (version=TLS1_3 cipher=TLS_AES_256_GCM_SHA384 bits=256/256); Mon, 30 Mar 2026 15:07:49 -0700 (PDT) Received-SPF: pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.14 as permitted sender) client-ip=69.67.186.14; Authentication-Results: mx.google.com; dkim=pass header.i=@bhmta.beehiiv.com header.s=bh header.b=dy1gcyWb; dkim=pass header.i=@mail.beehiiv.com header.s=bh header.b=GqQm0gPL; spf=pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.14 as permitted sender) smtp.mailfrom="bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=beehiiv.com X-BmtaRef: eyJfQF8iOiJcXF8vIiwicmVjaXBpZW50IjoidGpwaHVoc0BnbWFpbC5jb20iLCJ4X2xpc3RfaWQiOiJmZDQxNjMwZS1lOTFmLTQ2ZDktYTI3NC1iNzQwZGFiNzU2ZDIiLCJ4X3N1YnNjcmliZXJfaWQiOiI5YzQwZDYzOS02ZTFkLTQyOTItYTlkNy0wZTRjYmJiNWQ1ZGIifQ== DKIM-Signature: v=1; a=rsa-sha256; d=bhmta.beehiiv.com; s=bh; c=relaxed/relaxed; bh=FT5sMOdO/zpAmf/7BcGaaSHFfpJbt4udw6QHWSIGC6A=; h=from:subject:mime-version:content-type:content-transfer-encoding: list-unsubcribe:feedback-id:list-unsubscribe-post:reply-to:to:cc: content-type:feedback-id:from:subject:to; t=1774908468; b=dy1gcyWbtoVbUNT32h2D30ycb4wnxwqfJY5Az5N4cO2y0IuFmkt38YE4kctJrOBKZP1EYIN17 Se1auwNJVek5Aw4UW+UbA85uGNsDiyS39452gpNAF6yJ9nvoiCH3DyeHHKHEVGYBLmdpX0ATQQZ sJ8hexei58IrTOUONrnv/B6rAOsulKcEHT7PWGl0/66Gb4sudqxpkhe2wjJpEKTteySWTbzIF+z rKnzE8TtVfNqKevyQL0BmsJXldjSQ7olk5WPckLwnT81MnlxTpAbqTNj+S/+Do6d+mxlBUAenZs n97etqQc69ARQDHjm4RE4YobJVAljoADIfSQ8JZkdhRg==; DKIM-Signature: v=1; a=rsa-sha256; d=mail.beehiiv.com; s=bh; c=relaxed/relaxed; bh=FT5sMOdO/zpAmf/7BcGaaSHFfpJbt4udw6QHWSIGC6A=; h=from:subject:mime-version:content-type:content-transfer-encoding: list-unsubcribe:feedback-id:list-unsubscribe-post:reply-to:to:cc: content-type:feedback-id:from:subject:to; t=1774908468; b=GqQm0gPLlXhx8m8iA/gsVhFVLja3IogLyI4hatO61H4BPFPqXC760ZTWpw5ARbSBrX8ANI8w2 685aI7D63QlXdkrsYV6X6ljSxS8uoTW0DhES6rRFtCzS0P1hlZvJbLz2nRtOcH73y2Ko6uL/XIZ hojJgiMEvkMz4tpGh0dny/XgXwD8r5OngBD/YMHuH10qsFaojKFvsaKoXHOF6jql0TEMkPu1cKo 31n8cmnjlA6Ld72LLt8sgULkVK8WnfHfFzq2qV+Lbaw9vaQAPRyJNcmEShbZrblqsRyadI5MNGM NLor2Ooz22hYk4muidyGdg9Qndde2knn1JUefWbgCVOw==; Received: from mail.beehiiv.com by bhmta(mta24) with HTTP id for ; Mon, 30 Mar 2026 22:07:48 +0000 Content-Type: multipart/alternative; boundary="OUrPtgdBTUWgENFBHvrjuw" To: "tjphuhs@gmail.com" Feedback-ID: 14d360ca-7277-483d-a017-e2162499229b:newsletter:fd41630e-e91f-46d9-a274-b740dab756d2:c8f61fda6a60803 From: Hunter Williams List-Unsubscribe: , List-Unsubscribe-Post: List-Unsubscribe=One-Click Reply-To: =?utf-8?Q?Hunter=27s_Health_Hacks?= Subject: TB-500 for Alzheimer's? X-Batch-Id: 9b9d4e55-9511-4890-9cbe-42b1ca67ed6d X-Subscriber-ID: 9c40d639-6e1d-4292-a9d7-0e4cbbb5d5db sId: fd41630e-e91f-46d9-a274-b740dab756d2 x-beehiiv-ids: {"account_name":"https://huntershealthhacks.beehiiv.com/","campaign_id":"14d360ca-7277-483d-a017-e2162499229b","category":"newsletter","email_generated_at":1774908467,"user_id":"fd41630e-e91f-46d9-a274-b740dab756d2"} x-beehiiv-type: newsletter x-list-id: fd41630e-e91f-46d9-a274-b740dab756d2 x-list-owner: x-newsletter: https://huntershealthhacks.beehiiv.com/p/tb-500-for-alzheimer-s x-newsletter-id: https://huntershealthhacks.beehiiv.com/ x-newsletter-signup: https://huntershealthhacks.beehiiv.com/subscribe Mime-Version: 1.0 Date: Mon, 30 Mar 2026 22:07:48 +0000 Message-ID: <20260330.220748.fba43dda@mta24> --OUrPtgdBTUWgENFBHvrjuw Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable Happy Monday! =0A=0AMost people think of TB-500 as strictly a peptide for h= ealing injuries, and rightfully so.=0A=0AHowever, [a new study just dropped= in ](https://www.sciencedirect.com/science/article/abs/pii/S15675769250208= 67)_[International Immunopharmacology](https://www.sciencedirect.com/scienc= e/article/abs/pii/S1567576925020867)_ that examines TB-500 through the lens= of brain function.=0A=0AAnd the results are worth your time.=0A=0AToday, I= =E2=80=99ll break down what this research team actually did, what they foun= d, how the peptide appears to be working inside the brain, and what this co= uld mean for the future of Alzheimer=E2=80=99s research. =0A=0A=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=0A=0A**The Study**=0A=0AThe researchers in this study tested two fra= gments of thymosin beta-4. The first is TB-500. That's the actin-binding fr= agment most of you know. =0A=0AThe second is Ac-SDKP. That's a smaller frag= ment from the other end of the thymosin beta-4 molecule. It's known mostly = for its anti-inflammatory and anti-fibrotic activity.=0A=0AFull-length T=CE= =B24 is a relatively large peptide at nearly 5,000 daltons. That size makes= it harder to cross the blood-brain barrier. TB-500 and Ac-SDKP are much sm= aller. The thinking was that these fragments might actually reach the brain= more effectively than the parent molecule.=0A=0AThey tested both fragments= in lab-grown brain cells and in living mice with Alzheimer's-like disease.= =0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=0A=0A**The Brain Cell Test**=0A=0AThe team started= with two types of brain cells.=0A=0AFirst, they used HT22 cells and primar= y cortical neurons. =0A=0AThese are brain cells that can be grown in a dish= . They exposed these cells to amyloid-beta (A=CE=B2), which is the toxic pr= otein fragment that builds up in Alzheimer's brains and kills neurons. Then= they treated the cells with TB-500 and Ac-SDKP to determine whether the pe= ptides could protect them.=0A=0ASecond, they used BV2 microglia. =0A=0AMicr= oglia are the brain's resident immune cells. In a healthy brain, they clean= up debris and protect neurons. In Alzheimer's, they get stuck in an aggres= sive, inflammatory state called M1 polarization. =0A=0AWhen microglia go M1= , they release inflammatory chemicals that damage the neurons around them. = =0A=0AThe researchers activated these microglia with LPS (a bacterial toxin= that triggers inflammation) and then tested whether the peptides could cal= m them down.=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**The Results **=0A=0AIn the neur= ons exposed to amyloid-beta, both TB-500 and Ac-SDKP did three things.=0A= =0A1. They protected cell viability. Fewer neurons died when the peptides w= ere present. =0A=0A2. They reduced the expression of genes linked to progra= mmed cell death (apoptosis). =0A=0A3. They rescued neurite atrophy. Neurite= s are the branch-like extensions that neurons use to communicate with each = other. When neurites shrink, the brain's communication network breaks down.= That's a major driver of cognitive decline in Alzheimer's. Both peptides h= elped preserve those connections.=0A=0AIn the microglia experiments, the re= sults were just as clear. =0A=0ABoth TB-500 and Ac-SDKP suppressed nitric o= xide production, a marker of inflammatory activation. They reduced the expr= ession of pro-inflammatory cytokines. And they blocked M1 microglial polari= zation. =0A=0AIn plain terms, the peptides helped shift the brain's immune = cells from "attack mode" back toward a calmer, less destructive state.=0A= =0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=0A=0A**The Mice Test**=0A=0AThe team also used TB-500= and Ac-SDKP in 5xFAD mice. =0A=0AThis is one of the most aggressive Alzhe= imer's mouse models available. These mice carry five different mutations li= nked to familial Alzheimer's disease. They develop amyloid plaques early. T= hey show neuroinflammation. They lose cognitive function.=0A=0AThe research= ers treated these mice with TB-500 and Ac-SDKP and then ran two gold-standa= rd behavioral tests.=0A=0AThe Morris water maze is a fun way to test how we= ll mice can learn and remember spatial tasks. In this test, mice are placed= in a pool of water and need to find a hidden platform to escape. =0A=0AMic= e with Alzheimer's-like symptoms often take a bit longer and make more mist= akes, which helps researchers understand their memory challenges. =0A=0AThe= novel object recognition test is another interesting test that assesses wh= ether a mouse can tell the difference between something it has seen before = and something new, and it also relies on working memory. =0A=0AThese tests = provide valuable insights into how memory works in mice and can help us bet= ter understand memory issues, such as those seen in Alzheimer's disease.=0A= =0AView image: (https://media.beehiiv.com/cdn-cgi/image/fit=3Dscale-down,fo= rmat=3Dauto,onerror=3Dredirect,quality=3D80/uploads/asset/file/8f8e6af6-589= b-4d3f-a142-2a8189dc4e3e/image.png?t=3D1774904780)=0AFollow image link: (ht= tps://www.sciencedirect.com/science/article/abs/pii/S1567576925020867)=0ACa= ption: [https://www.sciencedirect.com/science/article/abs/pii/S156757692502= 0867](https://www.sciencedirect.com/science/article/abs/pii/S15675769250208= 67)=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=0A=0A**What They Found**=0A=0AThe treated mice = performed significantly better on both tests.=0A=0AIn the Morris water maze= , mice that received TB-500 or Ac-SDKP found the platform faster and more e= fficiently than untreated 5xFAD mice. =0A=0AIn the novel object recognition= test, treated mice showed better ability to distinguish new objects from f= amiliar ones. Their memory was measurably improved.=0A=0AThen the researche= rs examined what was happening in the brains of these mice.=0A=0AAnalysis s= howed that glial activation was markedly reduced in treated mice. That mean= s microglia and astrocytes were less inflamed. Neuronal apoptosis was also = reduced. Fewer brain cells were dying.=0A=0AThe peptides also restored axon= al density in the perirhinal cortex. The perirhinal cortex is a brain regio= n involved in object recognition and memory. =0A=0AIn Alzheimer's disease, = the nerve fibers in this area degenerate. TB-500 and Ac-SDKP appeared to he= lp preserve or rebuild those fibers.=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**The Amy= loid Plaque Question**=0A=0AInterestingly, the peptides did NOT reduce the = overall amyloid plaque burden in the hippocampus.=0A=0AThe plaques were sti= ll there. But the mice still got better. Their memory improved. Their neuro= ns survived at higher rates. Their inflammation went down. Their axonal con= nections were preserved.=0A=0AThis is a significant finding. It challenges = the idea that you have to clear amyloid plaques to improve Alzheimer's outc= omes. =0A=0AThe authors specifically note that their results "challenge the= A=CE=B2-centric therapeutic paradigm." The peptides worked by making the b= rain more resilient to the damage plaques cause, rather than by removing th= e plaques themselves.=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**What This Means for th= e Future**=0A=0AThis is the first study I've seen that directly tests TB-50= 0, the actual synthetic fragment, in a rigorous Alzheimer's model. Not just= the full-length thymosin beta-4. =0A=0AThe fact that both TB-500 and Ac-SD= KP improved memory in 5xFAD mice without clearing amyloid plaques opens a f= undamentally different therapeutic conversation. =0A=0AIt suggests that neu= ronal resilience and inflammation control might matter more than plaque rem= oval. That idea has been building across the neurology field, and this stud= y adds real weight to it.=0A=0AThe authors themselves note several areas th= at still need work. =0A=0ABlood-brain barrier penetration needs to be direc= tly measured for both fragments. =0A=0ADirect neuronal targets need further= identification. And they flag that sex-dependent responses need to be stud= ied, since AD affects men and women differently.=0A=0A=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A= =0A**Final Thoughts**=0A=0AThis is early-stage research, but it's well-desi= gned. =0A=0AThe fact that TB500 and Ac-SDKP improved cognitive outcomes, re= duced neuroinflammation, preserved axonal density, and protected neurons fr= om death, all without reducing plaque burden, is a genuinely important find= ing.=0A=0AIt won't change clinical practice tomorrow, but it should change = the conversation about where peptide research is headed.=0A=0AThe next time= you go to load up some TB-500, know that you are doing your brain a world = of good! =0A=0ABest,=0A=0AHunter Williams =0A=0A=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**S= ource:**=0A=0AOu H, Chen R, Zhou L, Zhang Y, Zhao S, Yang Z. ["Thymosin =CE= =B24-derived peptides alleviate neuroinflammation and neurite atrophy in bo= th in vitro models and in vivo 5=C3=97FAD mice: A potential therapy for mem= ory improvement in Alzheimer's disease."](https://www.sciencedirect.com/sci= ence/article/abs/pii/S1567576925020867) _International Immunopharmacology_.= 2025. doi: 10.1016/j.intimp.2025.116097.=0A=0A=0A=E2=80=94=E2=80=94=E2=80= =94=0A=0AYou are reading a plain text version of this post. For the best ex= perience, copy and paste this link in your browser to view the post online:= =0Ahttps://huntershealthhacks.beehiiv.com/p/tb-500-for-alzheimer-s --OUrPtgdBTUWgENFBHvrjuw Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable TB-500 for Alzheimer's?
New study just released=  ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌

March 30, 2026   |   Read online

TB-500 for Alzheimer's?

New study ju= st released

<= td align=3D"left" valign=3D"middle">
 
3D"share
 
=3D"share
 
3D"share
3D"share
3D""

The Study

<= td class=3D"dd" align=3D"left" style=3D"padding:0px 15px;text-align:left;wo= rd-break:break-word;">

Second, they used BV2 microglia.

Happy Monday!

Most peo= ple think of TB-500 as strictly a peptide for healing injuries, and rightfu= lly so.

However, a new study just = dropped in International Immunopharmacology that examines TB-500 through th= e lens of brain function.

An= d the results are worth your time.

Today, I=E2=80=99ll break down what this research team actually did,= what they found, how the peptide appears to be working inside the brain, a= nd what this could mean for the future of Alzheimer=E2=80=99s research.

 

The researchers in this study tested two fragments of thymosin bet= a-4. The first is TB-500. That's the actin-binding fragment most of you= know.

The second is Ac-SDK= P. That's a smaller fragment from the other end of the thymosin beta-4 = molecule. It's known mostly for its anti-inflammatory and anti-fibrotic= activity.

Full-length T=CE= =B24 is a relatively large peptide at nearly 5,000 daltons. That size makes= it harder to cross the blood-brain barrier. TB-500 and Ac-SDKP are much sm= aller. The thinking was that these fragments might actually reach the brain= more effectively than the parent molecule.

They tested both fragments in lab-grown brain cells and in = living mice with Alzheimer's-like disease.

=
 

The B= rain Cell Test

The team= started with two types of brain cells.

First, they used HT22 cells and primary cortical neurons.

These are brain cells that can= be grown in a dish. They exposed these cells to amyloid-beta (A=CE=B2), wh= ich is the toxic protein fragment that builds up in Alzheimer's brains = and kills neurons. Then they treated the cells with TB-500 and Ac-SDKP to d= etermine whether the peptides could protect them.

Microglia are the brain's resident immune = cells. In a healthy brain, they clean up debris and protect neurons. In Alz= heimer's, they get stuck in an aggressive, inflammatory state called M1= polarization.

When microgl= ia go M1, they release inflammatory chemicals that damage the neurons aroun= d them.

The researchers act= ivated these microglia with LPS (a bacterial toxin that triggers inflammati= on) and then tested whether the peptides could calm them down.

 

The Results

In the neurons exposed to amyloid-beta, both TB-500 and Ac-SDKP did three = things.

  1. They protecte= d cell viability. Fewer neurons died when the peptides were present.

  2. They reduced the expression of genes linked to programmed ce= ll death (apoptosis).

  3. They rescued neurite atrophy. Ne= urites are the branch-like extensions that neurons use to communicate with = each other. When neurites shrink, the brain's communication network bre= aks down. That's a major driver of cognitive decline in Alzheimer's= . Both peptides helped preserve those connections.

In the microglia experiments, the re= sults were just as clear.

Both TB-500 and Ac-SDKP suppressed nitric oxide production, a marker of in= flammatory activation. They reduced the expression of pro-inflammatory cyto= kines. And they blocked M1 microglial polarization.

In plain terms, the peptides helped shift the brai= n's immune cells from "attack mode" back toward a calmer, les= s destructive state.

<= tr><= td class=3D"dd" align=3D"left" style=3D"padding:0px 15px;text-align:left;wo= rd-break:break-word;">

The peptides also restored axonal density in the per= irhinal cortex. The perirhinal cortex is a brain region involved in object = recognition and memory.

<= tr>

What This Means for the Future

=
 

The Mice Test

The team also used TB-500 and Ac-SDKP in= 5xFAD mice.

This is one of= the most aggressive Alzheimer's mouse models available. These mice car= ry five different mutations linked to familial Alzheimer's disease. The= y develop amyloid plaques early. They show neuroinflammation. They lose cog= nitive function.

The researc= hers treated these mice with TB-500 and Ac-SDKP and then ran two gold-stand= ard behavioral tests.

The Mo= rris water maze is a fun way to test how well mice can learn and remember s= patial tasks. In this test, mice are placed in a pool of water and need to = find a hidden platform to escape.

Mice with Alzheimer's-like symptoms often take a bit longer and = make more mistakes, which helps researchers understand their memory challen= ges.

The novel object recog= nition test is another interesting test that assesses whether a mouse can t= ell the difference between something it has seen before and something new, = and it also relies on working memory.

These tests provide valuable insights into how memory works in m= ice and can help us better understand memory issues, such as those seen in = Alzheimer's disease.

3D""=

https://www.sciencedirect.com/science/article/abs/pii/S156757692= 5020867

 =

What They Found<= /b>

The treated mice perform= ed significantly better on both tests.

In the Morris water maze, mice that received TB-500 or Ac-SDKP f= ound the platform faster and more efficiently than untreated 5xFAD mice.

In the novel object recogniti= on test, treated mice showed better ability to distinguish new objects from= familiar ones. Their memory was measurably improved.

Then the researchers examined what was happening = in the brains of these mice.

Analysis showed that glial activation was markedly reduced in treated mice= . That means microglia and astrocytes were less inflamed. Neuronal apoptosi= s was also reduced. Fewer brain cells were dying.

In = Alzheimer's disease, the nerve fibers in this area degenerate. TB-500 a= nd Ac-SDKP appeared to help preserve or rebuild those fibers.

 

The Amyloid Plaque Question

Interestingly, the peptides did NOT reduce the overall amylo= id plaque burden in the hippocampus.

The plaques were still there. But the mice still got better. Their= memory improved. Their neurons survived at higher rates. Their inflammatio= n went down. Their axonal connections were preserved.

This is a significant finding. It challenges the = idea that you have to clear amyloid plaques to improve Alzheimer's outc= omes.

The authors specifica= lly note that their results "challenge the A=CE=B2-centric therapeutic= paradigm." The peptides worked by making the brain more resilient to = the damage plaques cause, rather than by removing the plaques themselves.

 

This is the first study I've seen that di= rectly tests TB-500, the actual synthetic fragment, in a rigorous Alzheimer= 's model. Not just the full-length thymosin beta-4.

The fact that both TB-500 and Ac-SDKP improved= memory in 5xFAD mice without clearing amyloid plaques opens a fundamentall= y different therapeutic conversation.

It suggests that neuronal resilience and inflammation control mi= ght matter more than plaque removal. That idea has been building across the= neurology field, and this study adds real weight to it.

The authors themselves note several areas that= still need work.

Blood-br= ain barrier penetration needs to be directly measured for both fragments. <= /span>

Direct neuronal targets need= further identification. And they flag that sex-dependent responses need to= be studied, since AD affects men and women differently.

 
Final Thoughts

This= is early-stage research, but it's well-designed.

The fact that TB500 and Ac-SDKP improved cogniti= ve outcomes, reduced neuroinflammation, preserved axonal density, and prote= cted neurons from death, all without reducing plaque burden, is a genuinely= important finding.

It won&#= 39;t change clinical practice tomorrow, but it should change the conversati= on about where peptide research is headed.

The next time you go to load up some TB-500, know that you a= re doing your brain a world of good!

Best,

Hunter Willi= ams

 

Source:

Ou H, Chen R, Zhou L, Zhang Y, Zhao S, Yang Z. "Thymosin = =CE=B24-derived peptides alleviate neuroinflammation and neurite atrophy in= both in vitro models and in vivo 5=C3=97FAD mice: A potential therapy for = memory improvement in Alzheimer's disease."=C2=A0International Immunopharmacology. 2025. doi: 10.1016/j.intimp.2025.116097.

3D"ig"3D"yt"<= /td>
<= td id=3D"join-my-private-coaching-group-the-" class=3D"dd" align=3D"left" v= align=3D"top" style=3D"color:#2A2A2A;font-weight:normal;padding:0px 15px;te= xt-align:left;">

=F0=9F=91=89Join my priva= te coaching group, The AXION Collective:

=
3D""

Wan= t more? Here=E2=80=99s how you can work with me:

=F0=9F=91=89Try Zeroats, the world=E2=80=99s first sugar-free, natural= ly flavored oatmeal:

=

=F0=9F=91=89Get the Peptide Cheat Sheet:

=

=F0=9F=91=89All my daily essentials on Amazon

=F0=9F=91=89Get discounts on your favorite pept= ides and research chemicals:

=F0=9F=91=8910% off the BEST workout supplements f= rom Unmatched Supps (pre-workout, whey protein, creatine, EAAs, electrolyte= s - use code HUNTERW at checkout):

=F0=9F=91=89Submit A Video Topic For My = Next YouTube Video:

Update your email preferences or unsu= bscribe here

© 2026 Hunter's Health Hac= ks

228 Park Ave S, #29976, New York, New York 10003, United States =

3D"beehiivPower= ed by beehiiv
Terms of = Service